Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 26;9(10):1467.
doi: 10.3390/children9101467.

Intrinsic Kidney Pathology in Children and Adolescents Following COVID-19 Vaccination: A Systematic Review

Henry H L Wu  1 , Mohan Shenoy  2   3 , Philip A Kalra  3   4 , Rajkumar Chinnadurai  3   4
Affiliations
Review

Intrinsic Kidney Pathology in Children and Adolescents Following COVID-19 Vaccination: A Systematic Review

Henry H L Wu et al. Children (Basel). .

Abstract

Global COVID-19 vaccination programs for children and adolescents have been developed with international clinical trial data confirming COVID-19 mRNA vaccine safety and efficacy for the pediatric population. The impact of COVID-19 vaccination in the kidneys is thought to be explained by a complex immune-mediated relationship between the two, although the pathophysiological mechanisms of how COVID-19 vaccination potentially induces kidney pathology are not presently well known. Whilst intrinsic kidney pathologies following COVID-19 vaccination have been reported in adults, such cases are only being recently reported with greater frequency in children and adolescents. Conforming to the PRISMA checklist, we conducted a systematic review of the current literature to provide an overview on the range of intrinsic kidney pathologies that have been reported following COVID-19 vaccination in children and adolescents. All English language research articles published on or before 30 June 2022 reporting new-onset or relapsed intrinsic kidney pathology in children or adolescents (≤18 years) following COVID-19 vaccination were selected for qualitative analysis. Out of 18 cases from the 13 published articles selected, there were 10 cases of IgA nephropathy (1 case of rapidly progressive glomerulonephritis requiring acute hemodialysis), 5 cases of minimal change disease (MCD), 1 case of concurrent MCD/tubulointerstitial nephritis (TIN) and 2 cases of TIN. There is no indication currently to avoid vaccination, unless specific circumstances exist, as the benefits of COVID-19 vaccination far outweigh its risks. Concluding the findings from our systematic review based on preliminary evidence, potential adverse effects to the kidney from COVID-19 vaccination affects a small number of children and adolescents among the many who have been vaccinated. There remains good reason at present to support vaccination of children and adolescents with a greater morbidity status, such as those living with preexisting chronic kidney disease. Close observation of all children and adolescents receiving COVID-19 vaccination is recommended, particularly in those with preceding intrinsic kidney pathology to identify risks of relapsed disease.

Keywords: COVID-19 vaccination; adolescents; children; intrinsic kidney pathology; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA Flow Diagram.
See this image and copyright information in PMC

References

    1. World Health Organization WHO Coronavirus Disease (COVID-19) Dashboard. [(accessed on 18 September 2022)]. Available online: https://covid19.who.int/
    1. Chakraborty I., Maity P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Sci. Total Environ. 2020;728:138882. doi: 10.1016/j.scitotenv.2020.138882. - DOI - PMC - PubMed
    1. Ewer K.J., Barrett J.R., Belij-Rammerstorfer S., Sharpe H., Makinson R., Morter R., Flaxman A., Wright D., Bellamy D., Bittaye M., et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat. Med. 2021;27:270–278. doi: 10.1038/s41591-020-01194-5. - DOI - PubMed
    1. Ali K., Berman G., Zhou H., Deng W., Faughnan V., Coronado-Voges M., Ding B., Dooley J., Girard B., Hillebrand W., et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N. Engl. J. Med. 2021;385:2241–2251. doi: 10.1056/NEJMoa2109522. - DOI - PMC - PubMed
    1. Walter E.B., Talaat K.R., Sabharwal C., Gurtman A., Lockhart S., Paulsen G.C., Barnett E.D., Muñoz F.M., Maldonado Y., Pahud B.A., et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N. Engl. J. Med. 2022;386:35–46. doi: 10.1056/NEJMoa2116298. - DOI - PMC - PubMed

LinkOut - more resources